Latest news
Iconovo carries out a directed issue of shares of approx. SEK 25 million and a rights issue of shares of approx. SEK 24.6 million
The Board of Directors of Iconovo AB ("Iconovo" or the "Company") has today resolved on a directed share issue of approximately SEK 25 million (the…
Iconovo appoints Anders Månsson as new CEO
Iconovo AB (publ), a leader in the development of inhalable drugs based on proprietary inhalers and dry powder formulations, has today appointed Anders…
Press releases
Dec 14, 2021, 10:30
News
IR
Swedish
Corporate Information
Other Corporate Information
Dec 14, 2021, 10:30
News
IR
English
Corporate Information
Other Corporate Information
Nov 19, 2021, 07:18
News
IR
English
Regulatory
MAR
Corporate Information
Sales
Order
Nov 19, 2021, 07:18
News
IR
Swedish
Regulatory
MAR
Corporate Information
Sales
Order
Nov 15, 2021, 12:00
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
Nomination Committee
Nov 15, 2021, 12:00
News
IR
English
Regulatory
Listing Regulation
Corporate Information
Nomination Committee
Nov 01, 2021, 09:00
News
IR
Swedish
Corporate Information
Other Corporate Information
Nov 01, 2021, 09:00
News
IR
English
Corporate Information
Other Corporate Information
Oct 29, 2021, 08:11
News
IR
English
Corporate Information
Other Corporate Information
Oct 28, 2021, 08:30
News
IR
Swedish
Regulatory
MAR
Report
Interim
Q3
Sep 22, 2021, 15:15
News
IR
Swedish
Corporate Information
Other Corporate Information
Sep 20, 2021, 09:00
News
IR
English
Corporate Information
Other Corporate Information
Sep 20, 2021, 09:00
News
IR
Swedish
Corporate Information
Other Corporate Information
Sep 15, 2021, 09:00
News
IR
Swedish
Corporate Information
Other Corporate Information
Aug 26, 2021, 14:09
News
IR
English
Corporate Information
Other Corporate Information
Aug 26, 2021, 14:09
News
IR
Swedish
Corporate Information
Other Corporate Information
Aug 25, 2021, 08:00
News
IR
Swedish
Corporate Information
Other Corporate Information
Aug 23, 2021, 11:04
News
IR
English
Corporate Information
Other Corporate Information
Aug 20, 2021, 08:30
News
IR
Swedish
Regulatory
MAR
Report
Interim
Q2
Jul 12, 2021, 09:00
News
IR
English
Regulatory
MAR
Corporate Information
Sales
Order
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se
Interim CEO
Anders Månsson
Mail: anders.mansson@iconovo.se